SWOG Cancer Research Network
@swog.org
SWOG Cancer Research Network runs publicly funded clinical trials that have saved 3 million+ years of life. Founded by the National Cancer Institute in 1956. Member NCTN & NCORP. Online at swog.org. @SupportingSWOG.bsky.social partner.
From our @swog.org group chair's Front Line blog:
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
November 7, 2025 at 7:33 PM
From our @swog.org group chair's Front Line blog:
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Stories of SWOG Accrual Stars
We have many inspiring stories of members and sites going above and beyond to enroll robustly to our trials.
www.swog.org/news-events/...
Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S.
lung-map.org
@focr.bsky.social @swog.org
lung-map.org
@focr.bsky.social @swog.org
November 6, 2025 at 5:02 PM
Lung-MAP 3.0’s easier genetic screening process means the Lung-MAP trial will be even better positioned to enroll a group of patients fully representative of the population of patients with advanced #NSCLC in the U.S.
lung-map.org
@focr.bsky.social @swog.org
lung-map.org
@focr.bsky.social @swog.org
Our @swog.org group chair's Front Line blog:
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
November 4, 2025 at 12:53 PM
Our @swog.org group chair's Front Line blog:
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Group Meeting Surveys: You "Talk," We Listen
SWOG has now held 2 group meetings under the new 3-day model (trimmed from 4 days previously). What do the surveys say?
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
October 31, 2025 at 4:21 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
doi.org/10.1177/1179...
Our @swog.org group chair's Front Line blog:
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
October 27, 2025 at 3:46 PM
Our @swog.org group chair's Front Line blog:
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
SWOG Research Demonstrates the Special Role of Federal Sponsorship
Presentation at #ASCOQLTY25 provides yet more evidence of the essential role of federal support in cancer research.
www.swog.org/news-events/...
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
October 17, 2025 at 8:35 PM
The S2409 PRISM #ClinicalTrial asks if we can treat extensive stage small cell lung cancer more effectively by targeting the vulnerabilities of specific molecular subtypes of the disease. #SCLC #LCSM
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
PI: Anne Chiang, MD, PhD, Yale Cancer Center
swog.org/clinical-trials/S2409
Our @swog.org group chair's blog:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
October 17, 2025 at 3:52 PM
Our @swog.org group chair's blog:
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Welcoming SWOG’s New Myeloma Leader: Dr. Amrita Y. Krishnan
I'm delighted to introduce Dr. Krishnan as new chair of SWOG’s Barlogie-Salmon myeloma committee, as of Nov 1!
swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
October 17, 2025 at 3:50 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Targeting STAT3 for Cancer Therapy: Focusing on Y705, S727, or Dual Inhibition?
doi.org/10.3390/canc...
Our fall 2025 @swog.org group meeting was a memorable one! Recordings of hybrid sessions (ie, most open sessions) will be available to SWOG members soon, behind password on swog.org. Watch the website! www.swog.org/swog-fall-20... #SWOGonc @supportingswog.bsky.social
September 22, 2025 at 5:24 PM
Our fall 2025 @swog.org group meeting was a memorable one! Recordings of hybrid sessions (ie, most open sessions) will be available to SWOG members soon, behind password on swog.org. Watch the website! www.swog.org/swog-fall-20... #SWOGonc @supportingswog.bsky.social
The @swog.org Latin America Initiative Symposium at the fall group meeting is discussing collaboration on breast cancer research. In updates from member sites, Dr. Tatiana Vidaurre, of Peru's INEN, reports on a project using AI to assist w breast cancer diagnoses.
September 20, 2025 at 3:14 PM
The @swog.org Latin America Initiative Symposium at the fall group meeting is discussing collaboration on breast cancer research. In updates from member sites, Dr. Tatiana Vidaurre, of Peru's INEN, reports on a project using AI to assist w breast cancer diagnoses.
KICKOFF session for S2427 BRIGHT trial,
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
September 18, 2025 at 7:20 PM
KICKOFF session for S2427 BRIGHT trial,
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
Fri, 9/19, 4:15-5:15 pm CT,
in-person AND online,
SWOG group meeting.
S2427 BRIGHT tests IO + RT as bladder-preserving treatment for patients with #MIBC who respond to NAT.
Find the Zoom link at
www.swog.org/swog-fall-20...
Later today, Thurs, 9/18, 2:30-4-:30 pm CT, at the
@swog.org group meeting, our Take Action Symposium takes on the challenges of bringing clinical trials to patients in rural areas. In-person and online.
swog.org/swog-fall-20...
@swog.org group meeting, our Take Action Symposium takes on the challenges of bringing clinical trials to patients in rural areas. In-person and online.
swog.org/swog-fall-20...
September 18, 2025 at 5:05 PM
Later today, Thurs, 9/18, 2:30-4-:30 pm CT, at the
@swog.org group meeting, our Take Action Symposium takes on the challenges of bringing clinical trials to patients in rural areas. In-person and online.
swog.org/swog-fall-20...
@swog.org group meeting, our Take Action Symposium takes on the challenges of bringing clinical trials to patients in rural areas. In-person and online.
swog.org/swog-fall-20...
SWOG members headed to Chicago (some virtually) for #SWOGonc fall mtg, Sep 18-20! Kickoffs for S2427 BRIGHT & Triple Switch, talks on ⬆️ enrollment of older & rural patients, plenary reflecting on progress in public-powered #CancerResearch, #NCORP trials wkshp, much more!
www.swog.org/news-events/...
www.swog.org/news-events/...
September 17, 2025 at 3:03 PM
SWOG members headed to Chicago (some virtually) for #SWOGonc fall mtg, Sep 18-20! Kickoffs for S2427 BRIGHT & Triple Switch, talks on ⬆️ enrollment of older & rural patients, plenary reflecting on progress in public-powered #CancerResearch, #NCORP trials wkshp, much more!
www.swog.org/news-events/...
www.swog.org/news-events/...
Our @swog.org group chair's blog:
Fall Group Meeting: The More Things Change …
Our fall plenary looks at #cancerresearch advances since
SWOG's last changing of the guard. We also kick off new trials (incl S2427 BRIGHT #bladderpreservation trial) & much more! #SWOGonc
swog.org/news-events/...
Fall Group Meeting: The More Things Change …
Our fall plenary looks at #cancerresearch advances since
SWOG's last changing of the guard. We also kick off new trials (incl S2427 BRIGHT #bladderpreservation trial) & much more! #SWOGonc
swog.org/news-events/...
September 16, 2025 at 1:02 PM
Our @swog.org group chair's blog:
Fall Group Meeting: The More Things Change …
Our fall plenary looks at #cancerresearch advances since
SWOG's last changing of the guard. We also kick off new trials (incl S2427 BRIGHT #bladderpreservation trial) & much more! #SWOGonc
swog.org/news-events/...
Fall Group Meeting: The More Things Change …
Our fall plenary looks at #cancerresearch advances since
SWOG's last changing of the guard. We also kick off new trials (incl S2427 BRIGHT #bladderpreservation trial) & much more! #SWOGonc
swog.org/news-events/...
S1800E is a Lung-MAP non-match sub-study. Randomized ph 2/3: docetaxel & ramucirumab w or w/o cemiplimab in patients w previous platinum-based chemo & IO for stage IV or recurrent NSCLC.
PI: Saima Waqar, MD, MSCI @sitemancenter.bsky.social
#lcsm #LungCancer
PI: Saima Waqar, MD, MSCI @sitemancenter.bsky.social
#lcsm #LungCancer
September 10, 2025 at 2:27 PM
S1800E is a Lung-MAP non-match sub-study. Randomized ph 2/3: docetaxel & ramucirumab w or w/o cemiplimab in patients w previous platinum-based chemo & IO for stage IV or recurrent NSCLC.
PI: Saima Waqar, MD, MSCI @sitemancenter.bsky.social
#lcsm #LungCancer
PI: Saima Waqar, MD, MSCI @sitemancenter.bsky.social
#lcsm #LungCancer
Now OPEN: S2427 BRIGHT trial! In patients with #MIBC, can immunoradiotherapy after response to neoadjuvant therapy (cT0 or cT1) allow for bladder preservation?
🔜S2427 KICKOFF mtg, Sept 19, 4:15-5:15 pm CT 🕟
💻UROLOGISTS: Attend virtually! Learn more: swog.org/swog-fall-20...
🔜S2427 KICKOFF mtg, Sept 19, 4:15-5:15 pm CT 🕟
💻UROLOGISTS: Attend virtually! Learn more: swog.org/swog-fall-20...
September 9, 2025 at 4:58 PM
Now OPEN: S2427 BRIGHT trial! In patients with #MIBC, can immunoradiotherapy after response to neoadjuvant therapy (cT0 or cT1) allow for bladder preservation?
🔜S2427 KICKOFF mtg, Sept 19, 4:15-5:15 pm CT 🕟
💻UROLOGISTS: Attend virtually! Learn more: swog.org/swog-fall-20...
🔜S2427 KICKOFF mtg, Sept 19, 4:15-5:15 pm CT 🕟
💻UROLOGISTS: Attend virtually! Learn more: swog.org/swog-fall-20...
Our @swog.org group chair's Front Line blog:
Meet the Advocate: Bruce Wright
A retired Navy commander, SWOG patient advocate Bruce Wright has helped us in our efforts to make #NCTN clinical trials an option available to more U.S. military veterans at more VAMCs.
www.swog.org/news-events/...
Meet the Advocate: Bruce Wright
A retired Navy commander, SWOG patient advocate Bruce Wright has helped us in our efforts to make #NCTN clinical trials an option available to more U.S. military veterans at more VAMCs.
www.swog.org/news-events/...
September 8, 2025 at 12:26 PM
Our @swog.org group chair's Front Line blog:
Meet the Advocate: Bruce Wright
A retired Navy commander, SWOG patient advocate Bruce Wright has helped us in our efforts to make #NCTN clinical trials an option available to more U.S. military veterans at more VAMCs.
www.swog.org/news-events/...
Meet the Advocate: Bruce Wright
A retired Navy commander, SWOG patient advocate Bruce Wright has helped us in our efforts to make #NCTN clinical trials an option available to more U.S. military veterans at more VAMCs.
www.swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting CDK2 for Cancer Therapy
doi.org/10.1016/j.ce...
Targeting CDK2 for Cancer Therapy
doi.org/10.1016/j.ce...
September 8, 2025 at 12:18 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Targeting CDK2 for Cancer Therapy
doi.org/10.1016/j.ce...
Targeting CDK2 for Cancer Therapy
doi.org/10.1016/j.ce...
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Antibody–Drug Conjugates as Multimodal Therapies Against Hard-to-Treat Cancers
doi.org/10.1016/j.ad...
Antibody–Drug Conjugates as Multimodal Therapies Against Hard-to-Treat Cancers
doi.org/10.1016/j.ad...
August 29, 2025 at 1:54 PM
Our #TranslationalMedicine Link of the Week, chosen by @swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Antibody–Drug Conjugates as Multimodal Therapies Against Hard-to-Treat Cancers
doi.org/10.1016/j.ad...
Antibody–Drug Conjugates as Multimodal Therapies Against Hard-to-Treat Cancers
doi.org/10.1016/j.ad...
S2417CD tests if the CTAC website —designed to educate, provide communication training, & more —can increase guideline-recommended surveillance among #CRC survivors w a support person.
Co-PIs: Christine Veenstra, MD, & Sarah Hawley, PhD
Rogel Cancer Center @umich.edu
swog.org/clinical-trials/S2417CD
Co-PIs: Christine Veenstra, MD, & Sarah Hawley, PhD
Rogel Cancer Center @umich.edu
swog.org/clinical-trials/S2417CD
August 22, 2025 at 3:41 PM
S2417CD tests if the CTAC website —designed to educate, provide communication training, & more —can increase guideline-recommended surveillance among #CRC survivors w a support person.
Co-PIs: Christine Veenstra, MD, & Sarah Hawley, PhD
Rogel Cancer Center @umich.edu
swog.org/clinical-trials/S2417CD
Co-PIs: Christine Veenstra, MD, & Sarah Hawley, PhD
Rogel Cancer Center @umich.edu
swog.org/clinical-trials/S2417CD
A Lung-MAP non-match sub-study is now enrolling: S1800E randomizes patients with advanced non-small cell #lungcancer to a standard docetaxel + ramucirumab combo w/wo cemiplimab. #NSCLC #lcsm
Biostatistician: Mary W. Redman, PhD
@fredhutch.bsky.social
swog.org/clinical-tri...
Biostatistician: Mary W. Redman, PhD
@fredhutch.bsky.social
swog.org/clinical-tri...
August 19, 2025 at 6:07 PM
A Lung-MAP non-match sub-study is now enrolling: S1800E randomizes patients with advanced non-small cell #lungcancer to a standard docetaxel + ramucirumab combo w/wo cemiplimab. #NSCLC #lcsm
Biostatistician: Mary W. Redman, PhD
@fredhutch.bsky.social
swog.org/clinical-tri...
Biostatistician: Mary W. Redman, PhD
@fredhutch.bsky.social
swog.org/clinical-tri...
From our @swog.org group chair's Front Line blog:
ESITC LeAPs into Its Next 25 Years
I'm proud to announce the names of members of the 2025 cohort of our Early Stage Investigator Training Course. And to announce a new name for the course itself.
swog.org/news-events/...
ESITC LeAPs into Its Next 25 Years
I'm proud to announce the names of members of the 2025 cohort of our Early Stage Investigator Training Course. And to announce a new name for the course itself.
swog.org/news-events/...
August 15, 2025 at 8:02 PM
From our @swog.org group chair's Front Line blog:
ESITC LeAPs into Its Next 25 Years
I'm proud to announce the names of members of the 2025 cohort of our Early Stage Investigator Training Course. And to announce a new name for the course itself.
swog.org/news-events/...
ESITC LeAPs into Its Next 25 Years
I'm proud to announce the names of members of the 2025 cohort of our Early Stage Investigator Training Course. And to announce a new name for the course itself.
swog.org/news-events/...
Our #TranslationalMedicine Link of the Week, chosen by
@swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design
doi.org/10.2147/DDDT...
@swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design
doi.org/10.2147/DDDT...
August 15, 2025 at 7:51 PM
Our #TranslationalMedicine Link of the Week, chosen by
@swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design
doi.org/10.2147/DDDT...
@swog.org's Lee Ellis, MD, & Jimmy Rae, PhD:
Artificial Intelligence-Driven Innovations in Oncology Drug Discovery: Transforming Traditional Pipelines and Enhancing Drug Design
doi.org/10.2147/DDDT...
Next-generation sequencing (NGS) of tumors has become a standard part of the treatment process for most patients with #NSCLC. Lung-MAP 3.0 can use results of a patient’s prior NGS testing to assign the patient to a targeted Lung-MAP sub-study. lung-map.org #lcsm
August 14, 2025 at 8:06 PM
Next-generation sequencing (NGS) of tumors has become a standard part of the treatment process for most patients with #NSCLC. Lung-MAP 3.0 can use results of a patient’s prior NGS testing to assign the patient to a targeted Lung-MAP sub-study. lung-map.org #lcsm
S2417CD is a pragmatic randomized #ClinicalTrial for post-surgery survivors of stage 2 or 3 #colorectal cancer (CRC) and their supporters. It tests an intervention to educate patients & promote partner engagement to help #CRC survivors get recommended follow-up surveillance.
August 13, 2025 at 3:57 PM
S2417CD is a pragmatic randomized #ClinicalTrial for post-surgery survivors of stage 2 or 3 #colorectal cancer (CRC) and their supporters. It tests an intervention to educate patients & promote partner engagement to help #CRC survivors get recommended follow-up surveillance.